Factors Influencing Statin Drug Comparisons
Author Information
Author(s): Lisa Bero, Fieke Oostvogel, Peter Bacchetti, Kirby Lee
Primary Institution: University of California, San Francisco
Hypothesis
The results and conclusions of trials are more likely to favor the statin made by the sponsor of the study.
Conclusion
Trials comparing statins are more likely to report results favoring the sponsor's product compared to the comparator drug.
Supporting Evidence
- 50% of the RCTs were funded by industry.
- 98% of studies used only surrogate outcome measures.
- Trials with adequate blinding were less likely to report results favoring the test drug.
Takeaway
This study found that when comparing statin drugs, the ones funded by the companies that make them often look better than those funded by others.
Methodology
Cross-sectional study analyzing 192 published RCTs comparing statin drugs.
Potential Biases
Funding source may influence outcomes and conclusions.
Limitations
Potential underestimation of industry-sponsored studies due to lack of disclosure.
Statistical Information
P-Value
p < 0.001
Confidence Interval
95% CI 4.37–92.98
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website